Showing 1051-1060 of 19239 results for "".
Pruritus In PN and AD: Challenge How You Manage Itch
https://reachmd.com/programs/cme/pruritus-in-pn-and-ad-challenge-how-you-manage-itch/36304/Use validated assessment tools to prioritize and measure itch in prurigo nodularis and atopic dermatitis in an interactive CME escape room.Diagnosing and Treating IBS: It Begins With One Simple Question
https://reachmd.com/programs/cme/diagnosing-and-treating-ibs-it-begins-with-one-simple-question/36607/Diagnosing and Treating IBS: It Begins With One Simple QuestionUnderstanding the MOA of NEMLUVIO®: Targeting IL-31 Signaling in Neuroimmune Skin Diseases
https://reachmd.com/programs/nemluvio-peer-network/understanding-the-moa-of-nemluvio-targeting-il-31-signaling-in-neuroimmune-skin-diseases/37128/Watch Dr Peter Lio as he explains the role of IL-31, a key neuroimmune cytokine, in AD and PN and provides an in depth overview of the mechanism of action for NEMLUVIO®.Next-Generation Innovations: The Future of CELMoDs in Myeloma
https://reachmd.com/programs/cme/next-generation-innovations-the-future-of-celmods-in-myeloma/36575/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityOptimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
https://reachmd.com/clinical-practice/nephrology/optimizing-igan-care-sparsentans-role-amid-the-latest-kdigo-guideline-updates/30044/Examine updated KDIGO 2025 IgAN guidelines and sparsentan’s role in managing proteinuria and slowing kidney function decline.Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
https://reachmd.com/programs/cme/tbd/37674/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.Seltorexant vs Quetiapine XR in MDD With Insomnia: A 26-Week Phase 3 Comparison
https://reachmd.com/clinical-practice/psychiatry-and-mental-health/seltorexant-vs-quetiapine-xr-in-mdd-with-insomnia-a-26-week-phase-3-comparison/37644/Compare efficacy, safety, and tolerability of adjunctive seltorexant versus quetiapine XR in MDD patients with insomnia symptoms.Menin Inhibitors: Biologic and Clinical Rationale
https://reachmd.com/programs/cme/menin-inhibitors-biologic-and-clinical-rationale/36179/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Early Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
https://reachmd.com/programs/heart-matters/early-initiation-of-acoramidis-in-attr-cm-importance-and-long-term-impacts/35757/Acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), was studied in an open-label extension of the ATTRibute-CM trial to determine whether its early and sustained use improves clinical outcomes. Discover acoramidis’ long-term impacts on all-cause mortality and/or first cardiovTreating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
https://reachmd.com/programs/project-oncology/treating-rr-classic-hodgkin-lymphoma-ipilimumab-and-other-approaches/26405/Read about the efficacy and safety of ipilimumab as a standalone treatment for relapsed or refractory classic Hodgkin lymphoma.